The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
Abstract
Purpose: To assess the prognostic value of the PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large cohort of postmenopausal, endocrine-responsive breast cancer patients. Experimental Design: The PAM50 assay was performed on formalin-fixed paraffin-embedded whole-tumor sections of patients who had been enrolled in the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-8). RNA expression levels of the PAM50 genes were determined centrally using the nCounter Dx Analysis System. Late distant recurrence-free survival (DRFS) was analyzed using Cox models adjusted for clinical and pathologic parameters. Results: PAM50 analysis was successfully performed in 1,246 ABCSG-8 patients. PAM50 ROR score and ROR-based risk groups provided significant additional prognostic information with respect to late DRFS compared with a combined score of clinical factors alone (ROR score: ΔLRχ2 15.32, P < 0.001; ROR-based risk groups: ΔLRχ2 14.83, P < 0.001). Between years 5 and 15, we observed an absolute risk of distant recurrence of 2.4% in the low ROR-based risk group, as compared with 17.5% in the high ROR-based risk group. The DRFS differences according to the PAM50 ROR score were observed for both node-positive and node-negative disease. Conclusion: PAM50 ROR score and ROR-based risk groups can differentiate patients with breast cancer with respect to their risk for late distant recurrence beyond what can be achieved with established clinicopathologic risk factors. Clin Cancer Res; 20(5); 1298–305. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Self-citation
Cited by
Clinical implications of the intrinsic molecular subtypes of breast cancer
Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015) · The Breast · doi:10.1016/j.breast.2015.07.008 · Cited by 1,319
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Solky, A. J., Stearns, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01160 · Cited by 636
Molecular Classification of Breast Cancer
Tsang, J. Y. S., & Tse, G. M. (2020) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000232 · Cited by 556
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., Snider, J., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0129-6 · Cited by 542
Self-citation
Metadata
- Authors
- Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stöger, H., Jakesz, R., Bago-Horvath, Z., Dietze, O., Regitnig, P., Gruber-Rossipal, C., Müller-Holzner, E., Singer, C. F., Mlineritsch, B., Dubsky, P., Bauernhofer, T., Hubalek, M., Knauer, M., Trapl, H., Fesl, C., Schaper, C., Ferree, S., Liu, S., Cowens, J. W., Gnant, M., & for the Austrian Breast and Colorectal Cancer Study Group
- Venue
- Clinical Cancer Research
- Published
- 2014-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1298-1305
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2108505891
- Cited by
- 215
- References
- 1
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1845
- The paper
- Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stöger, H., Jakesz, R., Bago-Horvath, Z., Dietze, O., Regitnig, P., Gruber-Rossipal, C., Müller-Holzner, E., Singer, C. F., Mlineritsch, B., Dubsky, P., Bauernhofer, T., Hubalek, M., Knauer, M., Trapl, H., Fesl, C., . . . for the Austrian Breast and Colorectal Cancer Study Group. (2014). The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1845
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.